熱門資訊> 正文
开盘前上涨股包括OPEN、BCRX和AWIN
2024-05-15 21:25
- Gainers: SINTX Technologies (SINT) +186%.
- Faraday Future Intelligent Electric (FFIE) +82%.
- Edible Garden AG (EDBL) +82% after Q1 earnings release.
- AERWINS Technologies (AWIN) +33%.
- Greenwave Technology Solutions (GWAV) +34%.
- Nyxoah SA (NYXH) +25% reports first Quarter 2024 financial and operating results.
- Dolphin Entertainment (DLPN) +24% after Q1 earnings release.
- Monday.Com Ltd (MNDY) +20% after Q1 earnings release.
- Arcutis Biotherapeutics (ARQT) +17% after Q1 earnings release.
- T2 Biosystems (TTOO) +15% announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules.
- Nextracker (NXT) +14% after Q4 earnings release.
- Acurx Pharmaceuticals (ACXP) +16% after Q1 earnings release.
- Safety Shot (SHOT) +13% announces strategic C-Store plans in Los Angeles.
- Biocryst Pharmaceuticals (BCRX) +11%.
- WiSA Technologies (WISA) +8% drives licensing business opportunities.
- Olema Pharmaceuticals (OLMA) +10% announces promising new data for Palazestrant in combination with Ribociclib.
- Sportradar Group (SRAD) +10% after Q1 earnings release.
- Ferroglobe (GSM) +9% after Q1 earnings release.
- BYND Cannasoft Enterprises (BCAN) +9%.
- Humacyte (HUMA) +9%.
- Petco Health and Wellness Co (WOOF) +9% appoints Glenn Murphy as executive chairman of the board.
- Dynatrace (DT) +9% after Q4 earnings release.
- Treace Medical Concepts (TMCI) +9%.
- Opendoor Technologies (OPEN) +8%.
More on Pre-market gainers & stocks.
- 5 Reasons To Buy Opendoor
- BioCryst: Estimate-Beating Q1 But Risks Are Considerable
- BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript
- BioCryst surges 18% on quarterly earnings, adjusted guidance outlook
- BioCryst Pharmaceuticals beats top-line and bottom-line estimates; updates FY24 outlook
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
